Cardiac resynchronization therapy combined with coronary artery bypass grafting in XXXX @entity1 : long-term results of the RESCUE study.

@entity1 @entity177 @entity712 @entity204
OBJECTIVES: Totally epicardial cardiac resynchronization therapy (CRT) is a novel treatment modality for @entity1 with @entity712 ( @entity712 ) and systolic dyssynchrony undergoing coronary artery bypass grafting (CABG). In this study, we have prospectively evaluated the long-term outcomes of totally epicardial CRT. METHODS: Between September 2007 and June 2009, one hundred and seventy-eight @entity1 were randomly assigned to the CABG alone group (n = 87) and CABG with concomitant epicardial CRT implantation (n = 91). The primary end-point of the study was all-cause mortality in the two groups between the day of surgery and 13 August 2013 (common closing date). The secondary outcomes included mode of @entity204 , adverse cardiac events and lead performance. RESULTS: The mean follow-up was 55    10.7 months. According to per-protocol analysis with treatment as a time-dependent variable to account for conversion from CABG to CABG + CRT, there were 24 @entity204 (35.8%) in the CABG group and 17 @entity204 (15.3%) in the CABG + CRT group. When compared with CABG alone, concomitant CRT was associated with reduced risk of both all-cause mortality [hazard ratio (HR) 0.43, 95% confidence interval (CI) 0.23-0.84, P = 0.012] and @entity204 (HR 0.39, 95% CI 0.21-0.72, P = 0.002). Eleven (12.6%) sudden @entity204 were observed in the CABG group in comparison with 4 (4.4%) in the CABG + CRT group (P = 0.048). Hospital readmission was required for 9 (9.9%) @entity1 in CABG + CRT group and for 25 (28.7%) @entity1 in the CABG group (P = 0.001). There were 4 (1.5%) @entity177 . CONCLUSIONS: The results of our study suggest that the procedure of CABG and totally epicardial CRT system implantation is safe and significantly improves the survival of @entity1 with @entity712 and dyssynchrony during long-term follow-up. CLINICAL TRIAL REGISTRATION: NCT 00846001 (http://www.clinicaltrials.gov).
